Keep checking on thyroid during use of antineoplastic agents

Share this content:

People with cancer who are being treated with antineoplastic agents should undergo routine testing for thyroid abnormalities, as these medications are associated with thyroid dysfunction in 20% to 50% or more of these patients.

The newer antineoplastic agents (such as immunotherapies and targeted therapies specifically zeroing in the signaling pathways in cancer cells) that are linked with thyroid problems include tyrosine kinase inhibitors, bexarotene, radioiodine-based cancer therapies, denileukin diftitox, alemtuzumab, interferon-alpha, interleukin-2, ipilimumab, tremelimumab, thalidomide, and lenalidomide. A recent literature review of the thyroid-related side effects of these treatments revealed that underdiagnosis of thyroid dysfunction can have important consequences for cancer patient management, according to the investigative team, which was led by Ole-Petter Riksfjord Hamnvik, MB, BCh, BAO, MRCPI, of the Division of Endocrinology, Diabetes, and Hypertension in the Department of Medicine at Brigham and Women's Hospital in Boston, Massachusetts.

As Hamnvik's group notes in the Journal of the National Cancer Institute, clinicians may overlook drug-induced thyroid dysfunction because of the complexity of the clinical picture in such patients. The investigators found that symptoms of hypothyroidism such as fatigue, weakness, depression, memory loss, cold intolerance, and cardiovascular effects may be incorrectly attributed to the primary disease or to the antineoplastic agent. Such symptoms can lead to dose reductions of potentially life-saving therapies. In addition, hypothyroidism can alter the kinetecs and clearance of medications, leading to undesirable side effects. The patient's quality of life may also be adversely affected. In some cases, thyroid disease may also indicate a higher likelihood of tumor response to the agent.

Specific tests make hypothyroidism and thyrotoxicosis easy and inexpensive to diagnose, and treatment is straightforward. Therefore, Hamnvik and colleagues suggest that persons who are receiving antineoplastic agents be tested regularly for thyroid abnormalities.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs